Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab, Toripalimab, and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
NCT05291910Phase 4Not yet recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inetetamab in breast cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression Free Survival at 24 months. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05291910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291910.